Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Therapeutic cancer vaccines are a key area of tumor immunotherapy.
• Clinical trials of peptide-based cancer vaccines have shown limited success in tumor regression.
• Current vaccination strategies may fail due to insufficient induction of cytotoxic T lymphocytes (CTLs), as precursor levels are often unmeasured.

Purpose of the Study:

• To investigate the detectability of cytotoxic T lymphocytes-precursors (CTL-p) reacting to potential cancer vaccine peptides in pre-vaccination peripheral blood mononuclear cells (PBMCs).
• To assess if pre-existing CTL-p levels correlate with anti-cancer cytotoxicity.
• To explore the feasibility of a CTL-p-oriented peptide vaccine approach.

Main Methods:

• Analyzed pre-vaccination PBMCs from 80 cancer patients for CTL-p reactivity to 28 candidate vaccine peptides (13 for HLA-A24(+) and 15 for HLA-A2(+) patients).
• Assessed HLA-class-I-restricted cytotoxicity of PBMCs against cancer cells after incubation with identified positive peptides.
• Examined the variability of peptide-specific CTL-p profiles among patients and their relation to cancer origin.

Main Results:

• Peptide-specific CTL-p were detected in 71% (57 out of 80) of cancer patients.
• On average, positive cases showed reactivity to 2.0 peptides.
• PBMCs incubated with positive peptides demonstrated significant HLA-class-I-restricted cytotoxicity against cancer cells, unlike those with negative peptides.
• The reactivity profiles varied significantly between patients and were independent of cancer type.

Conclusions:

• Pre-existing peptide-specific CTL-p are common in cancer patients.
• The presence of CTL-p correlates with functional anti-cancer cytotoxicity.
• These findings support a novel CTL-p-oriented strategy for developing personalized peptide vaccines in cancer immunotherapy.